This profile is for informational purposes only and is not medical advice. Consult a healthcare professional before use. See full terms.
PRL-8-53
A synthetic nootropic developed at Creighton University that showed dramatic improvements in word recall in a double-blind study - with subjects over 30 showing 80-100% improvement, though research remains extremely limited to a single 1978 trial.
Benefits
What is PRL-8-53?
PRL-8-53 (methyl 3-(2-(benzhydryloxy)ethyl)aminobenzoate hydrochloride) is a synthetic nootropic compound developed by Dr. Nikolaus Hansl at Creighton University in the 1970s. The compound's name derives from Hansl's personal research lab designation. Despite being one of the least studied nootropics, PRL-8-53 has maintained a devoted following in the cognitive enhancement community based on the remarkable results of its only published human trial - a double-blind, placebo-controlled study conducted by Hansl and Redrobe in 1978, published in Psychopharmacology.
In this pivotal study, 47 healthy volunteers were given either 5 mg of PRL-8-53 or placebo before a word acquisition task involving memorising 12 monosyllabic words. While the overall group showed moderate improvement, the subgroup analysis revealed striking results: subjects over the age of 30 who initially scored below average on the word recall task demonstrated 80-100% improvement in retrieval performance 24 hours and one week after initial learning compared to placebo. The study also suggested enhanced consolidation rather than acquisition, as the benefits appeared most clearly in delayed recall tests. Despite these promising findings, no further clinical trials were ever conducted, and Dr. Hansl passed away in 2011 without securing funding for additional research. The mechanism of action remains poorly characterised, though animal studies by Hansl suggested involvement of both dopaminergic and cholinergic pathways, along with possible potentiation of serotonin activity.
- Dopaminergic enhancement: Animal studies suggest PRL-8-53 may potentiate dopamine signalling, supporting attention, working memory, and the motivational salience needed for memory encoding
- Cholinergic modulation: May enhance acetylcholine transmission in memory-related circuits, potentially explaining its effects on consolidation and retrieval of verbal information
- Serotonergic potentiation: Early pharmacological profiling suggested partial serotonin-enhancing activity, which could contribute to improved cognitive flexibility and information processing
- Memory consolidation enhancement: The 1978 study's results - with benefits most apparent in delayed recall at 24 hours and one week - suggest PRL-8-53 primarily strengthens the consolidation phase of memory rather than initial encoding
- Possible glutamatergic involvement: The compound's structural features suggest potential interaction with excitatory neurotransmitter systems involved in long-term potentiation, though this has not been directly studied
- Research dosage: 5 mg was the single dose used in the only human clinical trial, administered orally before the learning task
- Community-reported range: 5-10 mg per dose is the most commonly reported range among nootropic users, taken 30-60 minutes before cognitively demanding tasks
- Sublingual use: Some users report sublingual administration at 2-5 mg for faster onset, though no formal pharmacokinetic data supports this route
- Frequency: Typically used acutely (as needed) rather than daily, often before study sessions, exams, or demanding cognitive work
- Duration of effects: Based on the original study, cognitive benefits appear to persist for at least one week after a single dose, suggesting long-lasting effects on memory consolidation
- Extremely limited safety data: Only 47 human subjects have been formally studied, all receiving a single 5 mg dose. No long-term safety data, repeated-dose studies, or toxicology reports exist in the published literature
- Original study safety: In the 1978 trial, no adverse effects were reported at the 5 mg dose. Dr. Hansl reportedly self-experimented extensively without noting significant side effects
- Community reports: Anecdotal reports from nootropic users generally describe PRL-8-53 as well-tolerated, with occasional reports of mild headache, jaw tension, or restlessness at higher doses
- Unknown interactions: No drug interaction studies have been conducted. Caution is warranted when combining with dopaminergic or serotonergic medications given the compound's proposed mechanisms
- Unregulated status: PRL-8-53 is not approved for medical use in any country and is sold as a research chemical. Purity and accurate dosing cannot be guaranteed without independent testing
Natural Sources & Forms
- Research chemical vendors: Available from select nootropic suppliers as powder or pre-dosed capsules, typically in 5 mg units
- No pharmaceutical production: PRL-8-53 has never been manufactured by a pharmaceutical company and has no approved medical use anywhere in the world
- Powder form: Most commonly available as the hydrochloride salt in powder form, requiring accurate milligram-scale measurement
- Solution form: Some vendors offer PRL-8-53 in liquid solution for volumetric dosing precision
Frequently Asked Questions
A synthetic nootropic developed at Creighton University that showed dramatic improvements in word recall in a double-blind study - with subjects over 30 showing 80-100% improvement, though research remains extremely limited to a single 1978 trial.
The key benefits of PRL-8-53 include: Cognitive Enhancement, Creativity, Focus, Memory, Motivation.
Dopaminergic enhancement: Animal studies suggest PRL-8-53 may potentiate dopamine signalling, supporting attention, working memory, and the motivational salience needed for memory encoding Cholinergic modulation: May enhance acetylcholine transmission in memory-related circuits, potentially explaining its effects on consolidation and retrieval of verbal information Serotonergic potentiation: Early pharmacological profiling suggested partial serotonin-enhancing activity, which could contribute to improved cognitive flexibility and information processing Memory consolidation enhancement: The 1978 study's results - with benefits most apparent in delayed recall at 24 hours and one week - suggest PRL-8-53 primarily strengthens the consolidation phase of memory rather than initial encoding Possible glutamatergic involvement: The compound's structural features suggest potential interaction with excitatory neurotransmitter systems involved in long-term potentiation, though this has not been directly studied
Research dosage: 5 mg was the single dose used in the only human clinical trial, administered orally before the learning task Community-reported range: 5-10 mg per dose is the most commonly reported range among nootropic users, taken 30-60 minutes before cognitively demanding tasks Sublingual use: Some users report sublingual administration at 2-5 mg for faster onset, though no formal pharmacokinetic data supports this route Frequency: Typically used acutely (as needed) rather than daily, often before study sessions, exams, or demanding cognitive work Duration of effects: Based on the original study, cognitive benefits appear to persist for at least one week after a single dose, suggesting long-lasting effects on memory consolidation
Extremely limited safety data: Only 47 human subjects have been formally studied, all receiving a single 5 mg dose. No long-term safety data, repeated-dose studies, or toxicology reports exist in the published literature Original study safety: In the 1978 trial, no adverse effects were reported at the 5 mg dose. Dr. Hansl reportedly self-experimented extensively without noting significant side effects Community reports: Anecdotal reports from nootropic users generally describe PRL-8-53 as well-tolerated, with occasional reports of mild headache, jaw tension, or restlessness at higher doses Unknown interactions: No drug interaction studies have been conducted. Caution is warranted when combining with dopaminergic or serotonergic medications given the compound's proposed mechanisms Unregulated status: PRL-8-53 is not approved for medical use in any country and is sold as a research chemical. Purity and accurate dosing cannot be guaranteed without independent testing
Overall Rating
Log in to rate this nootropic.
Comments
Log in to leave a comment.
No comments yet. Be the first to share your experience!